CASC3 and head and neck cancer: Summarizing, although BTZ confers single agent activity against HNSCC cells in vitro and in vivo by inhibition of CIP2A, clinical trials with BTZ in head and neck cancer showed poor results, conceivably by induction of protective autophagy and overexpression of CIP2A.